↓ Skip to main content
What is this page? Embed badge

A multicenter phase 2 single arm study of cabozantinib in patients with advanced or unresectable renal cell carcinoma pre-treated with one immune-checkpoint inhibitor: The BREAKPOINT trial (Meet-Uro…

Overview of attention for article published in Tumori Journal, November 2022
Altmetric Badge

About this Attention Score

  • In the top 25% of all research outputs scored by Altmetric
  • Among the highest-scoring outputs from this source (#39 of 913)
  • High Attention Score compared to outputs of the same age (84th percentile)
  • High Attention Score compared to outputs of the same age and source (81st percentile)

Mentioned by

twitter
12 tweeters

Citations

dimensions_citation
2 Dimensions

Readers on

mendeley
16 Mendeley
Summary Twitter Dimensions citations
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Title
A multicenter phase 2 single arm study of cabozantinib in patients with advanced or unresectable renal cell carcinoma pre-treated with one immune-checkpoint inhibitor: The BREAKPOINT trial (Meet-Uro trial 03)
Published in
Tumori Journal, November 2022
DOI 10.1177/03008916221138881
Pubmed ID
36447337
Authors

Giuseppe Procopio, Mélanie Claps, Chiara Pircher, Luca Porcu, Pierangela Sepe, Valentina Guadalupi, Ugo De Giorgi, Davide Bimbatti, Franco Nolè, Francesco Carrozza, Sebastiano Buti, Roberto Iacovelli, Chiara Ciccarese, Cristina Masini, Cinzia Baldessari, Laura Doni, Antonio Cusmai, Angela Gernone, Sarah Scagliarini, Sandro Pignata, Filippo de Braud, Elena Verzoni

View on publisher site

Twitter Demographics

The data shown below were collected from the profiles of 12 tweeters who shared this research output. Click here to find out more about how the information was compiled.

Mendeley readers

The data shown below were compiled from readership statistics for 16 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Unknown 16 100%

Demographic breakdown

Readers by professional status Count As %
Unspecified 4 25%
Researcher 2 13%
Other 2 13%
Student > Postgraduate 2 13%
Student > Ph. D. Student 1 6%
Other 0 0%
Unknown 5 31%
Readers by discipline Count As %
Unspecified 4 25%
Medicine and Dentistry 3 19%
Biochemistry, Genetics and Molecular Biology 2 13%
Pharmacology, Toxicology and Pharmaceutical Science 1 6%
Unknown 6 38%

Attention Score in Context

This research output has an Altmetric Attention Score of 9. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 22 March 2023.
All research outputs
#3,678,691
of 23,572,509 outputs
Outputs from Tumori Journal
#39
of 913 outputs
Outputs of similar age
#70,378
of 452,904 outputs
Outputs of similar age from Tumori Journal
#2
of 11 outputs
Altmetric has tracked 23,572,509 research outputs across all sources so far. Compared to these this one has done well and is in the 84th percentile: it's in the top 25% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 913 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 12.1. This one has done particularly well, scoring higher than 95% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 452,904 tracked outputs that were published within six weeks on either side of this one in any source. This one has done well, scoring higher than 84% of its contemporaries.
We're also able to compare this research output to 11 others from the same source and published within six weeks on either side of this one. This one has done well, scoring higher than 81% of its contemporaries.

This page is provided by Altmetric.